Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) FCF Margin: 2010-2025

Historic FCF Margin for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to 5.06%.

  • Arrowhead Pharmaceuticals' FCF Margin fell 109759.00% to 5.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 18.91%, marking a year-over-year decrease of 255991.00%. This contributed to the annual value of 18.91% for FY2025, which is 1703722.00% up from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' FCF Margin stood at 5.06%, which was up 100.89% from -565.72% recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' 5-year FCF Margin high stood at 2,549.41% for Q2 2024, and its period low was -6,151.52% during Q4 2024.
  • Its 3-year average for FCF Margin is -682.44%, with a median of -40.33% in 2023.
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by 506,898bps in 2023, then soared by 297,521bps in 2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' FCF Margin (Quarterly) stood at -244.49% in 2021, then spiked by 6,154bps to -182.95% in 2022, then tumbled by 506,898bps to -5,251.93% in 2023, then plummeted by 89,959bps to -6,151.52% in 2024, then slumped by 109,759bps to 5.06% in 2025.
  • Its FCF Margin was 5.06% in Q3 2025, compared to -565.72% in Q2 2025 and 83.79% in Q1 2025.